EMA Knocks Back Pfizer’s Xeljanz For Rheumatoid Arthritis and Otsuka’s Delamanid For TB
The EMA has rejected Pfizer’s tofacitinib for the second time on safety grounds and Otsuka’s delamanid due to a short trial length.
The EMA has rejected Pfizer’s tofacitinib for the second time on safety grounds and Otsuka’s delamanid due to a short trial length.